Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

120
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
120
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

138
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
138
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

388
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
388
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

121
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
121
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

185
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
185
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

134
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
134

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dietary Intake of Chromista Oil Alters Hepatic Metabolomic Profile of Mice With Excess Fat Mass.

Nutrition and metabolic insights·2024
Same author

Efficacy and safety of leadless ventricular pacemaker: a single-center retrospective observational study.

Cardiovascular diagnosis and therapy·2024
Same author

Thermal Ablation for Papillary Thyroid Carcinoma.

JAMA otolaryngology-- head & neck surgery·2024
Same author

Effects of Ginseng on Cognitive Function: A Systematic Review and Meta-Analysis.

Phytotherapy research : PTR·2024
Same author

Metabolomic Alteration in Adipose Monocyte Chemotactic Protein-1 Deficient Mice Fed a High-Fat Diet.

Nutrition and metabolic insights·2024
Same author

Fracture Risk Prediction Using the Fracture Risk Assessment Tool in Individuals With Cancer.

JAMA oncology·2024

Related Experiment Video

Updated: Jun 6, 2025

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

819

The CCL5/CCR5 axis in ulcerative colitis.

Fan Fan Qu1, Ya Qian Wu2, Jian Bin Ji1

  • 1First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.

Cellular Immunology
|November 28, 2024
PubMed
Summary
This summary is machine-generated.

Ulcerative colitis (UC) involves inflammation linked to pro-inflammatory factors like CCL5. Targeting the CCL5/CCR5 axis with antagonists or agonists may offer new therapeutic strategies for UC treatment.

Keywords:
CCL5/CCR5 axisCCR5 agonistsCCR5 antagonistsSignaling pathwayUlcerative colitis

More Related Videos

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.3K
A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease
05:08

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease

Published on: March 1, 2022

3.8K

Related Experiment Videos

Last Updated: Jun 6, 2025

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

819
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.3K
A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease
05:08

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease

Published on: March 1, 2022

3.8K

Area of Science:

  • Immunology
  • Gastroenterology
  • Molecular Biology

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease with unclear etiology.
  • Imbalanced pro-inflammatory and anti-inflammatory molecular expression contributes to UC pathogenesis.
  • CCL5 (C-C chemokine ligand 5) is a key pro-inflammatory factor implicated in UC.

Purpose of the Study:

  • To elucidate the role of the CCL5/CCR5 axis and its signaling pathways in UC.
  • To explore the therapeutic potential of targeting the CCL5/CCR5 axis for UC treatment.

Main Methods:

  • Review of the function of the CCL5/CCR5 axis in UC pathogenesis.
  • Analysis of signaling pathways (PI3K/AKT, NF-κB, Ras/MAPK) activated by CCL5/CCR5.
  • Exploration of CCR5 antagonists and agonists as potential UC therapeutics.

Main Results:

  • CCL5/CCR5 axis activation promotes UC pathogenesis through downstream signaling.
  • The CCL5/CCR5 axis is a significant factor in UC inflammatory processes.
  • CCR5 antagonists and agonists show potential for modulating UC inflammation.

Conclusions:

  • The CCL5/CCR5 axis is a critical mediator in ulcerative colitis.
  • Targeting the CCL5/CCR5 pathway presents a promising therapeutic avenue for UC.
  • Further research into CCR5 modulators could lead to novel UC treatments.